Live Chat

CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 74.2 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder.Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

JnJ live diagram

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Hand holding mobile with Tesla logo and upward stock arrow, reflecting Tesla Model Y price increase.
Vanessa L 2025 Jan 23, 11:00

Tesla Model Y Price Hike Sparks Debate Across Canada

TSLA Stocks Shares
Gold bullion and U.S. dollar bills, reflecting trends in gold coin prices.
Vanessa L 2025 Jan 23, 10:20

Gold Coin Prices Steady Amid Dollar Weakness

Gold USD Commodities Fed
Apple stock news with Chinese flag on smartphone, highlighting market challenges.
Vanessa L 2025 Jan 23, 08:30

Apple Stock News Amid Revenue Diversification

Stocks Shares AAPL China
BOJ rate hike
Tommy Yap 2025 Jan 22, 17:00

Morning Note: BOJ’s Rate Hike: How Will It Shape Markets?

BoJ Forex
Netflix app logo on smartphone, representing "do Netflix stocks stay good or bad."
Vanessa L 2025 Jan 22, 12:30

Trump Stock Market & Netflix Stock Outlook

Stocks US500 USD Shares
Oil prices
Tommy Yap 2025 Jan 21, 17:00

Morning Note: How Trump's Energy Plan and Global Market Trends Are Shaping Investments

Oil
Frances Wang 2025 Jan 21, 16:00

NFLX stock News today: Netflix stock jumped over 14%

Stocks
Frances Wang 2025 Jan 21, 16:00

Dow Jones rises ahead of potential interest rate cuts

Indices

Info

Spread

0.94

Spread (%)

0.6415 %

Gearing

1:2

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market åben

Torsdag

14:31 - 20:59

Mandag

14:31-20:59

Tirsdag

14:31-20:59

Onsdag

14:31-20:59

Fredag

14:31-20:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

349754982400

Aktier udestående

2407620096

Indtjeningsdato (Næste)

2001-06-13

Udbytteprocent

2025-03-04

Ex-udbyttedato

2025-02-18

Forventet årlig udbyttesats

4.96

Forventet årlig udbytteprocent

0.0335

EPS

5.8

Få mere at vide om dette instrument

JnJ Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre
Relaterede instrumenter
Trustpilot
Live Chat